Article
Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.
European journal of nuclear medicine and molecular imaging - 1 Dec 2024
Zajicek Franziska, Verhaeghe Jeroen, De Lombaerde Stef, Van Eetveldt Annemie, Miranda Alan, Munoz-Sanjuan Ignacio, Dominguez Celia, Khetarpal Vinod, Bard Jonathan, Liu Longbin, Staelens Steven, Bertoglio Daniele
Abstract excerpt
PURPOSE: Positron emission tomography (PET) imaging of mutant huntingtin (mHTT) aggregates is a potential tool to monitor disease progression as well as the efficacy of candidate therapeutic interventions for Huntington's disease (HD). To date, the focus has been mainly on the investigation of 11C radioligands; however, favourable 18F radiotracers will facilitate future clinical translation. This work aimed at...
Topics
- Huntington Disease
- Animals
- Positron-Emission Tomography
- Huntingtin Protein
- Mice
- Fluorine Radioisotopes
- Protein Aggregates
- Ligands
- Brain
